Prof. Niek van Dijk is joining Episurf Medical’s Clinical Advisory Board
Episurf Medical AB (NASDAQ: EPIS B) is expanding its Clinical Advisory Board with the addition of Prof. Niek van Dijk. Prof. van Dijk is a leading authority for foot and ankle surgery globally and he has treated people across the world, including several leading athletes.
Prof. van Dijk is professor in orthopaedic surgery at the University of Amsterdam and he is the former head of the Orthopaedic Department of the AMC (Academic Medical Center) hospital in Amsterdam. He is currently working in the FIFA Medical Centres of Excellence in Madrid, Clinic Ripoll, de Prado & van Dijk (near Real Madrid Santiago Bernabéu Stadium) and in Porto, Clinica de Dragão (near FC Porto Dragão Stadium). Prof. van Dijk is editor in chief of the Journal of ISAKOS (JISAKOS) and has been in several international board positions, for example as president of the European Society for Sport Traumatology, Knee Surgery and Arthroscopy (ESSKA), the ankle section of ESSKA (ESSKA-AFAS), the Dutch Orthopedic Society and the Nordic Orthopedic Federation (NOF). He has published over 350 scientific articles, several books and presents on average at 25 international lectures a year.
“We are very happy to add Prof. van Dijk to our Clinical Advisory Board, as his knowledge and experience as a foot and ankle surgeon is second to none. As Episurf Medical has announced its intention to launch a patient-specific implant for the ankle joint, we could not have asked for a more skilled individual to join our team”, says Prof. Leif Ryd, Senior Medical Advisor at Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.20 CEST on 1 April 2019.
Tags: